Client NewsOKYO Pharma Limited: Interim results for the six months to 30 September 2021
OKYO Pharma Limited (LSE: OKYO) a biopharmaceutical company developing next-generation therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain today announces its interim results for the six months ended 30 September 2021.
· Total assets decreased to £4.2 million (31 March 2021: £5.1 million)
· Cash on hand of £3.8 million (31 March 2021: £5.0 million)
· During the financial period under review, the Company reported a total comprehensive loss of £1.8 million (restated 30
September 2020: total comprehensive loss £0.5 million).
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.